About Tigertext
TIGERTEXT BOARD OF DIRECTORS
BRAD BROOKS / CO-FOUNDER
Brad previously ran DIC Entertainment as President for 6 years after working for Donaldson, Lufkin and Jenrette as an Investment Banker. DIC was a children’s branded media company that produced, distributed and licensed content globally. After acquiring the company with Bain Capital from the Walt Disney Company in 2000, he helped grow the company from less than $10mm of revenues to over $80mm in 2005 when he took the company public on the London Stock Exchange at a $200mm valuation.
Brad received his BA from UC Berkeley and an MBA from the University of Chicago.
JEFFREY EVANS / CO-FOUNDER
Jeffrey has an extensive history in healthcare staffing. After working as SVP and General Manager at On Assignment (NASDAQ: ASGN), Jeffrey took over OnStaff as President and Chief Operating Officer which was sold to Hall Kinion (NASDAQ: HAKI). Jeffrey joined the HAKI management team as Senior Executive Vice President of Operations and, in 2004, helped complete the sale of HAKI to KForce (NASDAQ: KFRC). Evans is also the Chairman of the Board of Orion ICG the nation’s largest recruiting and placement organization specializing in the placement of individuals leaving the military.
Jeffrey received his B.A. from Emory University and an M.B.A. from the Fuqua School of Business at Duke University.
JOHN FRIEDMAN / DIRECTOR
John H. Friedman is the Founding and Managing Partner of Easton Capital Group. Prior to founding Easton Capital, John was the founder and Managing General Partner of Security Pacific Capital Investors. Security Pacific Capital Investors was a $200-million private equity fund geared towards expansion financings and recapitalizations.
Prior to joining Security Pacific, John was a Managing Director and Partner at E.M. Warburg, Pincus & Co., Inc., where he spent eight and a half years. During his tenure, John was involved in Warburg’s investments in Computerland, Tweeds, Babbages’ and US Healthcare. Previously, John was an attorney with Sullivan and Cromwell.
He holds a JD degree from Yale Law School and a BA degree, magna cum laude and Phi Beta Kappa, from Yale College. John currently serves on the Boards of Promedior, Experimed, Trellis Bioscience, Cardiovascular Systems, Xoft, iTherX, PlaySpan. He was also co-chairman of the President’s Council at the Cold Spring Harbor Laboratory and serves as a Trustee of The New Museum of Contemporary Art and the Neighborhood Coalition for Shelter.
HERBERT MADAN / DIRECTOR
Experienced venture investor in privately-held technology companies. Has over 22 years of technology and business leadership experience both as a serial entrepreneur and an operating executive. Present investments include: DATAllegro (acquired by MSFT), Postpath (acquired by CSCO), Ocarina Networks (acquired by DELL), Clairmail, Palo Alto Networks, Aster Data (acquired by Teradata), Yodle, Oodle, TRUSTe, DataGuise, SimOps Studios, Tigertext, Skout, Opinyun and PointInside. Notable prior accomplishments include: CEO & Founder of RouteScience Technologies (acquired by Avaya), VP/GM of Service Provider Network and Application Software Business at Cisco Systems, and CEO & Founder of NETSYS Technologies (acquired by CSCO).
INDER SINGH / DIRECTOR
Mr. Inder P. Singh brings 28 years of extensive experience and in-depth knowledge of the financial Industry and entrepreneurship. Inder has previously served as COO of Life Lock Inc. where he led the company’s growth from 30 K to 1.4 MM customers. Previously, Inder was Executive Vice President and Global CIO of Visa International, CEO and co- founder of EXLServices, COO for Card Capture Services, which was the owner of the third largest ATM network and later sold to E-Trade. Inder also worked at Bank of America, where he was Executive Vice President of Consumer Banking Product and Delivery Support, Executive Vice President of Payments Strategy and Interstate Banking and Executive Vice President of Global Wholesale Technology.
SOMU SUBRAMANIAM / DIRECTOR
Somu Subramaniam is Managing Partner of New Science Ventures- a New York based venture fund focused on science based investments with a significant focus on Life Sciences. Prior to New Science Ventures, Somu was at McKinsey & Company for 23 years (‘80-’03) where he was a Director (Senior Partner). At various points in his career at McKinsey, Somu was a leader of the Firm’s Healthcare, Strategy and Technology practices. Somu’s client base at McKinsey included several of the world’s largest pharmaceutical, biotechnology and medical device companies. This client base included major companies in the U.S., Europe and Asia. Somu’s other major life sciences investments include Light Sciences Oncology, Synta Pharmaceuticals and Bionicare. Somu has an MBA from the Harvard Business School and a Bachelor of Science degree from the Indian Institute of Technology.
RAJ VEMULAPALLI / DIRECTOR
Raj brings more than 11 years of messaging experience at Yahoo! (YHOO) where he served as Head of Engineering for Real-Time Communications Products, Platforms and Services. He lead Yahoo! Messenger and Yahoo! Mobile Messaging to #1 position in US and to #2 in the world with a reach of 280+ million active users and $150+ million annual revenues. In addition to developing for Yahoo and publishing extensively on the topic of messaging, Raj has six patents on real-time communications. Currently serving as Board of Director, Technology and Strategy advisor to emerging and disruptive companies, Raj received an MS in Computer Science from the University of Iowa and a BS in Computer Science & Engineering from Osmania University.
TIGERTEXT BOARD OF ADVISORS
Dr. Earl Warren Brien, M.D.
Earl Warren Brien, MD is the Director of Musculoskeletal Tumor Service at the Cedars-Sinai Orthopaedic Center. Dr. Brien received his specialty training in musculoskeletal tumors at Memorial Sloan-Kettering Cancer Center and metabolic bone disease at the Hospital for Special Surgery, Cornell University. A diplomate of the National Board of Medical Examiners and a diplomate of the American Board of Orthopaedic Surgery, Dr. Brien is a member of numerous professional societies, including the American Orthopaedic Association and the Association of Bone and Joint Surgeons. He was the Cancer Liaison Physician for the American College of Surgeons for over ten years. He has published numerous articles and has written book chapters in the area of bone and soft tissue tumors and metabolic bone disease. He has lectured nationally and internationally in these specialties as well. He lectures annually for the American Academy of Orthopaedic Surgeons Board Maintenance of Certification Preparation in principles of oncology, metabolic bone disease and infection.
Dr. Frank Litvack, M.D.
Frank Litvack M.D. is a native of Montreal, Canada. In 1979 he completed his residency in Internal Medicine at McGill University and completed his Cardiovascular Fellowship at Cedars-Sinai in Los Angeles in 1985. He is a an inductee in the NASA Space Technology Hall of Fame for his work translating Excimer laser technology from the Jet Propulsion Laboratories into the clinic. Dr. Litvack has been an entrepreneur in the medical technology industry having been involved in several successful start-up companies. These include; Chairman of Progressive Angioplasty Systems Inc., Chairman of Savacor Inc., that was sold to St. Jude Medical in 2005 and Chairman & CEO of Conor MedSystems Inc., a developer of drug delivery stents that was sold to Johnson and Jonson in 2007. Presently, Dr. Litvack is Co-Founder of Reprise Medical Technologies, a Medical Device Incubator. He is Co-Founder and Chairman of Entourage Medical Technologies a developer of novel devices for the treatment of Structural Heart Disease. Dr. Litvack serves on Boards of several companies including Entourage Medical (Structural Heart), Recor Medical (Structural Heart), Nile Therapeutics Inc (Specialty Pharmaceutical), One Lambda Inc (Molecular Diagnostics), Pervasis Therapeutics (Cell Therapy) and iTherx Pharmaceuticals (Biotechnology). He serves on the Health Advisory Board of RAND Corporation. Dr. Litvack is active in philanthropy and resides in Los Angeles, California.
Dr. Andrew A. Brooks, M.D., F.A.C.S.
Dr. Andrew A. Brooks, founded Cardo Medical, Inc. in May 2007 which was acquired by Arthrex in 2011. Dr. Brooks has been in the private practice of orthopedic surgery since 1994, specializing in sports medicine, arthroscopy and joint reconstruction. Prior to founding Cardo Medical, founded Specialty Surgical Center, and sold it to Symbion (NASDAQ; SMBI) in 2005. Dr. Brooks is board-certified by the American Board of Orthopedic Surgery and is a Fellow of the American Academy of Orthopedic Surgeons. He received his B.S. and M.D. degrees from University of Southern California. He completed his Residency in Orthopedic Surgery at the University of Southern California, and subsequently completed a fellowship in arthroscopic reconstructive surgery and sports medicine at the Hughston Clinic in Columbus, Georgia.
Dr. Rishi Manchanda MD MPH
Rishi Manchanda MD MPH is the founder and CEO of HealthBegins, a public health startup, and is a board-certified internist and pediatrician. Dr. Manchanda was the first graduate of UCLA Medical Center’s Combined Internal Medicine and Pediatrics Residency program and is an alumnus of the National Health Service Corps. Dr. Manchanda has led the development and redesign of healthcare delivery systems and the application of web-based and GIS tools to care for populations with complex medical and social needs, from working families in south Los Angeles to homeless Veterans. Dr.Manchanda is a nationally renowned expert in primary care, public health, and social determinants of health.
